18.14
Precedente Chiudi:
$17.20
Aprire:
$17.45
Volume 24 ore:
256.04K
Relative Volume:
0.75
Capitalizzazione di mercato:
$603.00M
Reddito:
$4.12M
Utile/perdita netta:
$-56.68M
Rapporto P/E:
-3.2727
EPS:
-5.5429
Flusso di cassa netto:
$-51.44M
1 W Prestazione:
+5.04%
1M Prestazione:
-1.55%
6M Prestazione:
-20.79%
1 anno Prestazione:
-28.92%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DNTH
Dianthus Therapeutics Inc
|
18.14 | 603.00M | 4.12M | -56.68M | -51.44M | -5.5429 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-20 | Iniziato | TD Cowen | Buy |
2024-10-03 | Iniziato | Oppenheimer | Outperform |
2024-07-26 | Iniziato | Robert W. Baird | Outperform |
2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
2024-05-16 | Iniziato | H.C. Wainwright | Buy |
2024-02-15 | Iniziato | Stifel | Buy |
2023-12-26 | Iniziato | Jefferies | Buy |
2023-11-22 | Iniziato | Wedbush | Outperform |
2023-10-30 | Iniziato | Guggenheim | Buy |
2023-09-28 | Iniziato | Raymond James | Outperform |
2022-08-25 | Downgrade | Goldman | Buy → Neutral |
2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
2021-08-20 | Ripresa | Goldman | Neutral |
2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
2021-07-22 | Reiterato | B. Riley Securities | Buy |
2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
2021-06-15 | Iniziato | BTIG Research | Buy |
2021-05-18 | Iniziato | B. Riley Securities | Buy |
2021-01-07 | Iniziato | Mizuho | Buy |
2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
2019-03-25 | Downgrade | Goldman | Buy → Neutral |
2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment - TipRanks
Equities Analysts Issue Forecasts for DNTH FY2026 Earnings - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%What's Next? - MarketBeat
California State Teachers Retirement System Sells 1,352 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Two Sigma Investments LP Sells 588 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Squarepoint Ops LLC Has $242,000 Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Millennium Management LLC Has $1.97 Million Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Bank of America Corp DE Sells 9,858 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat
Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat
Dianthus Therapeutics appoints new board member By Investing.com - Investing.com India
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz
Dianthus Therapeutics appoints new board member - Investing.com Australia
Dianthus Therapeutics Announces Board Changes and Elections - TipRanks
Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan
Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat
Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World
HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World
Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):